Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Can pharmacokinetic dosing decrease nephrotoxicity associated with aminoglycoside therapy

D J Leehey1, B I Braun, D A Tholl

  • 1Department of Medicine, Veterans Affairs Hospital, Hines, IL 60141.

Journal of the American Society of Nephrology : JASN
|July 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preventive effects of early immunosuppressive treatment on the development of interstitial lung disease in systemic sclerosis.

Rheumatology (Oxford, England)·2024
Same author

Disparity in utilization of combined kidney-liver transplantation in the United States.

Clinical transplantation·2009
Same author

New antimicrobial agents as therapy for resistant gram-positive cocci.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2007
Same author

Evaluation of proteinuria in healthy living kidney donor candidates.

Transplantation proceedings·2006
Same author

The effectiveness and safety of oral linezolid for the primary and secondary treatment of osteomyelitis.

Journal of chemotherapy (Florence, Italy)·2006
Same author

Surviving heat shock: control strategies for robustness and performance.

Proceedings of the National Academy of Sciences of the United States of America·2005
Same journal

Variants to Functions to Therapeutic Strategies Toward Genomically Informed Care for Autosomal Dominant Polycystic Kidney Disease.

Journal of the American Society of Nephrology : JASN·2026
Same journal

Personalizing Cardio-Kidney-Metabolic Therapy: Closer But Not There Yet.

Journal of the American Society of Nephrology : JASN·2026
Same journal

Autosomal Dominant Tubulointerstitial Kidney Disease: My Kingdom for a Biomarker.

Journal of the American Society of Nephrology : JASN·2026
Same journal

Beyond the Margin: Improving Noninferiority Trials of Kidney Transplant Immunosuppression.

Journal of the American Society of Nephrology : JASN·2026
Same journal

Parathyroid Hormone Receptor 1 Facilitates Cyst Growth in Genetic Models of Autosomal Dominant Polycystic Kidney Disease.

Journal of the American Society of Nephrology : JASN·2026
Same journal

Alanyl-tRNA Synthetase 1 and Cyst Growth in Autosomal Dominant Polycystic Kidney Disease.

Journal of the American Society of Nephrology : JASN·2026
See all related articles

Bayesian pharmacokinetic dosing did not reduce kidney damage from aminoglycoside antibiotics. This individualized dosing strategy did not lower the incidence or severity of nephrotoxicity in patients receiving these critical medications.

Area of Science:

  • Pharmacology
  • Clinical Pharmacy
  • Nephrology

Background:

  • Aminoglycoside antibiotics are crucial for treating severe infections.
  • Nephrotoxicity is a significant adverse effect of aminoglycoside therapy.
  • Optimizing aminoglycoside dosing may reduce toxicity.

Purpose of the Study:

  • To evaluate if Bayesian pharmacokinetic modeling improves aminoglycoside dosing.
  • To determine if individualized dosing reduces nephrotoxicity compared to standard care.

Main Methods:

  • A randomized controlled trial involving 243 patients receiving aminoglycosides.
  • Three groups: physician-directed dosing, pharmacist-assisted Bayesian dosing, and pharmacist-directed Bayesian dosing.
  • Nephrotoxicity assessed by serum creatinine levels.

Related Experiment Videos

Main Results:

  • Individualized dosing led to higher peak aminoglycoside levels and peak/MIC ratios.
  • No significant difference in nephrotoxicity incidence (16%, 27%, 16%) or severity across groups.
  • Identified risk factors for toxicity: therapy duration, shock, furosemide, age, liver disease.

Conclusions:

  • Bayesian pharmacokinetic dosing did not decrease nephrotoxicity risk from aminoglycosides.
  • Dosing intervention had no effect on nephrotoxicity after controlling for risk factors.
  • Standard dosing remains a viable option, with careful monitoring for risk factors.